Display options
Cite
Brites C, Alcântara AP, Mosqueira B, et al. Safety and Efficacy of Reduced Doses of Ritonavir (RTV) Plus Saquinavir (SQV) in the Treatment of AIDS Patients in Brazil. Braz J Infect Dis. 1999;3(3):91-96
Brites, C., Alcântara, A. P., Mosqueira, B., Gimbo, A., Pedroso, C., & Pedral-Sampaio, D. (1999). Safety and Efficacy of Reduced Doses of Ritonavir (RTV) Plus Saquinavir (SQV) in the Treatment of AIDS Patients in Brazil. The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases, 3(3), 91-96.
Brites, et al. "Safety and Efficacy of Reduced Doses of Ritonavir (RTV) Plus Saquinavir (SQV) in the Treatment of AIDS Patients in Brazil." The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases vol. 3,3 (1999): 91-96.
Brites C, Alcântara AP, Mosqueira B, Gimbo A, Pedroso C, Pedral-Sampaio D. Safety and Efficacy of Reduced Doses of Ritonavir (RTV) Plus Saquinavir (SQV) in the Treatment of AIDS Patients in Brazil. Braz J Infect Dis. 1999 Jun;3(3):91-96. PMID: 11097712.
Copy Download .nbib Format: NLM
Share it on

Braz J Infect Dis. 1999 Jun;3(3):91-96.

Safety and Efficacy of Reduced Doses of Ritonavir (RTV) Plus Saquinavir (SQV) in the Treatment of AIDS Patients in Brazil.

The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases

Brites, Alcântara, Mosqueira, Gimbo, Pedroso, Pedral-Sampaio

Affiliations

  1. University Hospital Prof. Edgard Santos Federal University of Bahia, Salvador, Bahia, Brazil.

PMID: 11097712

Abstract

The use of reduced doses of Ritonavir (RIT) and Saquinavir (SQV) is considered a potent alternative in treating patients infected by HIV-1. We tested a combination of 300mg of RIT plus 600mg of SQV, twice daily, in association with two reverse transcriptase inhibitors to treat AIDS patients for a period of 6 months. Evaluation of HIV-1 RNA plasma levels, CD4+/CD8+ cell count and biochemical/hematological parameters (liver enzymes, serum electrolytes, creatinin, blood glucose, uric acid, white blood cell count, platelet count, and hemoglobin level) were performed after 30, 90 and 180 days of therapy. Clinical failure and adverse reactions were also recorded in order to assess safety and efficacy of the treatment. A total of 30 AIDS patients (25 male; 5 female) were enrolled in the study. Eight patients discontinued the therapy due to intolerance, 2 patients presented clinical failure (onset of AIDS-defining events during the study period), 2 patients werc excluded due to protocol violation. Five patients tolerated only a lower dose of RIT (400mg/day). Patients who completed 6 months of therapy had a drop in viral load from 4.8+/-.7 log(10) median 4.9 log) to 3.4 +/- 1.0 log(10) (median 2.6 log), and an increase in CD4+ count from 109 +/- 86cells/ml (median 84cells/ml) to 249+/- 114 cells/ml (median 265 cells/ml), compared to baseline values. However, patients who used a lower dose of RIT (400mg/day) had a less impressive drop in viral load values (mean 0.6 log(10) NA copies/ml) when compared with those using the 600mg/day of the drug (mean 2.4 log(10)). The percentage of patients presenting undetectable levels of HIV-1 RNA in plasma was quite different for the 2 groups: 92% of patients with a viral load <400 RNA copies/ ml were using 600mg of RIT. The combination of reduced doses of RIT and SQV reduced viral load >1.0 log(10) after 6 months in 83% of study patients. The dose of 600mg/day of RIT was morc effective in reducing viral load than 400mg/day, but was less well-tolerated. CD4+ cell counts increased in all patients regardless of the RIT dose used.

Publication Types